Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.12 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: siltuximab, olokizumab, ziltivekimab +3 | 0.90 |
| trials ClinicalTrials.gov | 45 Parkinson's trials, 3 stopped | 0.95 |
| literature PubMed | 1,150 Parkinson's papers of 200,985: well-trodden | 0.07 |
| pathways Reactome | 13 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2295
Sealed predictions
- IL6 in dopamine neurons, braak+0.29 (p 0.443) → +0.43 (p 0.243)receipt 2302
Swarm cases
receipt 2302: IL6 in dopamine neurons, braak
- power
- full sample +0.40 (p 0.099, n 18), 95% CI -0.08 to +0.73. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.38 (p 0.118, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.31 (p 0.211, n 18). could be the mix.
- skeptic
- leave-one-out range +0.31 to +0.50, sign flips 0; without severely affected donors +0.40 (p 0.099, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL6 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts